Inozyme Pharma is headquartered in Boston, Massachusetts.
Inozyme Pharma disclosed revenue of 76M USD for 2023 and 69M USD for 2022.
Inozyme Pharma has 59 employees.
Inozyme Pharma is a life science company.
Inozyme Pharma was founded in 2015.
321 Summer Street, Suite 400,
Boston, Massachusetts
02210
United States,
(857) 330-4340
www.inozyme.com
Inozyme Pharma is a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. The company's lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. It has demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency. Inozyme Pharma was formed in 2015 and is based in Boston, Massachusetts.
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
